CL2014001754A1 - Una preparacion farmaceutica que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales y beta-ciclodextrina sustituida. - Google Patents

Una preparacion farmaceutica que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales y beta-ciclodextrina sustituida.

Info

Publication number
CL2014001754A1
CL2014001754A1 CL2014001754A CL2014001754A CL2014001754A1 CL 2014001754 A1 CL2014001754 A1 CL 2014001754A1 CL 2014001754 A CL2014001754 A CL 2014001754A CL 2014001754 A CL2014001754 A CL 2014001754A CL 2014001754 A1 CL2014001754 A1 CL 2014001754A1
Authority
CL
Chile
Prior art keywords
quinolin
thiophen
piperazin
cyclodextrin
benzo
Prior art date
Application number
CL2014001754A
Other languages
English (en)
Inventor
Tetsuya Hasegawa
Hidekazu Toyobuku
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47603961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001754(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of CL2014001754A1 publication Critical patent/CL2014001754A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014001754A 2011-12-28 2014-06-27 Una preparacion farmaceutica que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales y beta-ciclodextrina sustituida. CL2014001754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161580708P 2011-12-28 2011-12-28

Publications (1)

Publication Number Publication Date
CL2014001754A1 true CL2014001754A1 (es) 2014-10-03

Family

ID=47603961

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001754A CL2014001754A1 (es) 2011-12-28 2014-06-27 Una preparacion farmaceutica que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales y beta-ciclodextrina sustituida.

Country Status (20)

Country Link
US (4) US20150005314A1 (es)
EP (1) EP2797631A1 (es)
JP (1) JP6246715B2 (es)
KR (1) KR20140107378A (es)
CN (2) CN104023750A (es)
AR (1) AR089486A1 (es)
AU (1) AU2012360716B2 (es)
BR (1) BR112014015885A8 (es)
CA (1) CA2860282A1 (es)
CL (1) CL2014001754A1 (es)
CO (1) CO7010828A2 (es)
EA (1) EA201491288A1 (es)
HK (1) HK1198939A1 (es)
IL (1) IL233127A0 (es)
MX (1) MX2014007979A (es)
PH (1) PH12014501425A1 (es)
SG (2) SG10201605188UA (es)
TW (1) TW201332572A (es)
WO (1) WO2013100204A1 (es)
ZA (1) ZA201405039B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10349631B2 (en) * 2014-07-21 2019-07-16 Nicholas Jay Bonge, JR. Wireless animal training, monitoring and remote control system
JP6513461B2 (ja) * 2015-04-14 2019-05-15 帝國製薬株式会社 ブレクスピプラゾールの経皮吸収製剤
CN105078910B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
EP3545950A1 (en) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
CN115252585A (zh) * 2021-04-13 2022-11-01 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜包合物、其制备方法及应用
WO2022218358A1 (zh) * 2021-04-13 2022-10-20 上海博志研新药物技术有限公司 一种布瑞哌唑物口腔薄膜剂、其制备方法及应用
CN116763746A (zh) * 2022-03-08 2023-09-19 万全万特制药江苏有限公司 一种布瑞哌唑口崩片及其制备方法
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US580708A (en) 1897-04-13 Robert orme
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
ATE428423T1 (de) * 2002-08-20 2009-05-15 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Also Published As

Publication number Publication date
US20180008599A1 (en) 2018-01-11
CO7010828A2 (es) 2014-07-31
AR089486A1 (es) 2014-08-27
BR112014015885A2 (pt) 2017-06-13
ZA201405039B (en) 2015-12-23
HK1198939A1 (en) 2015-06-19
CN107261153A (zh) 2017-10-20
CN104023750A (zh) 2014-09-03
EP2797631A1 (en) 2014-11-05
PH12014501425A1 (en) 2014-09-22
AU2012360716A1 (en) 2014-07-31
US20170151237A1 (en) 2017-06-01
IL233127A0 (en) 2014-07-31
US20150005314A1 (en) 2015-01-01
CA2860282A1 (en) 2013-07-04
BR112014015885A8 (pt) 2017-07-04
NZ626379A (en) 2015-09-25
KR20140107378A (ko) 2014-09-04
US20160310617A1 (en) 2016-10-27
AU2012360716B2 (en) 2017-08-17
TW201332572A (zh) 2013-08-16
EA201491288A1 (ru) 2014-11-28
WO2013100204A1 (en) 2013-07-04
SG10201605188UA (en) 2016-07-28
JP2015503501A (ja) 2015-02-02
SG11201403308QA (en) 2014-07-30
MX2014007979A (es) 2014-08-21
JP6246715B2 (ja) 2017-12-13

Similar Documents

Publication Publication Date Title
CL2014001754A1 (es) Una preparacion farmaceutica que comprende 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales y beta-ciclodextrina sustituida.
CO6950480A2 (es) Tableta que contiene 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona o una de sus sales
EP2761911A4 (en) PERSONAL SALES POINT
ME03036B (me) 2-amin0-6-fluoro-n-( 5-fluoro-4-( 4-( 4-( oksetan -3-il)piperrazin -1-karbonil)piperidin-1-il)piridin-3-il )pirazol0[1,5alfa] pirimidin-3-karboksamid kao inhibitor atr kinaze
HUE037444T2 (hu) ACC inhibitorok és azok felhasználása
CO6821908A2 (es) Prenda absorbente desechable que tiene superficies coloreadas y una pretina integral
BR112014028458A2 (pt) papelão e bloco bruto de papelão.
EP2550879A4 (en) SMOKING ARTICLE
PL2828075T3 (pl) Papier, drukarka, zastosowanie papieru do produkcji etykiet i sposoby wytwarzania papieru
HRP20170928T1 (hr) Inhibitori kinurenin-3-monooksigenaze, farmaceutski pripravci, i postupci za njihovu upotrebu
IL229963A0 (en) Substituted quinolines and their use as medicaments
BR112016013254A2 (pt) Produto higiênico e produto absorvente
ME02905B (me) Heterociklična jedinjenja, medikamenti koji sadrže navedena jedinjenja, njihova primjena i postupak za njihovo dobijanje
FI20126266L (fi) Pehmopaperin mittaus
FI20115991L (fi) Pakkauskartonki, sen käyttö ja siitä valmistettuja tuotteita
FR3002214B1 (fr) Distributeur de sauce et condiments
CL2015000761A1 (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf-r
FI10901U1 (fi) Desinfiointi- ja/tai sterilointilaite
EP2731610A4 (en) PHARMACEUTICAL COMBINATION
HUE045066T2 (hu) Axmi115 variáns inszekticid gén és annak alkalmazásai
EP2824419A4 (en) CROSS-LINE LASER
PT2687523E (pt) Novos derivados de fenilpiridina e fármacos que os contêm
HRP20160687T1 (hr) Supstituirani 2-(kroman-6-iloksi)tiazoli i njihova upotreba kao farmaceutska sredstva
ES1074859U8 (es) Pulsera de identificación para pacientes en hospitales.
BR112013012958A2 (pt) inibidores integrin ligado com quinase